Whitehawk Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Whitehawk Therapeutics Inc <WHWK.OQ> expected to post a loss of 30 cents a share - Earnings Preview
Whitehawk Therapeutics Inc WHWK.OQ WHWK.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Whitehawk Therapeutics Inc is for a loss of 30 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $7.50, about 94.8% above its last closing price of $3.85
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.36 | -0.36 | -0.32 | Beat | 10.4 |
Dec. 31 2026 | -0.27 | -0.15 | -0.34 | Missed | -120.8 |
Sep. 30 2025 | -0.15 | 0.07 | -0.26 | Missed | -490 |
Jun. 30 2025 | 0.34 | 0.49 | -0.76 | Missed | -254.1 |
Mar. 31 2025 | -0.41 | -0.46 | -0.37 | Beat | 19.6 |
Dec. 31 2024 | -0.23 | -0.22 | -0.67 | Missed | -204.5 |
Sep. 30 2024 | -0.38 | -0.46 | -0.46 | Met | -0.5 |
Jun. 30 2024 | -0.69 | -0.69 | -0.54 | Beat | 21.7 |
This summary was machine generated August 3 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)